Chief Scientific Officer Dr Jeff Drew, uses a microscope to look at cells containing the novel coronavirus SARS-CoV-2 in the Stabilitech laboratory in Burgess Hill south east England, on May 15, 2020 where scientists are trying to develop an oral vaccine for the COVID-19 illness. - The scientists at Stabilitech are one of the teams attempting to develop a vaccine for COVID-19. Ingested in a capsule into the gut, Stabilitech's potential oral vaccine aims to prompt an immune response in mucosal cells in the respiratory system and elsewhere in the body. The firm believes that will be more effective in tackling respiratory illnesses like coronavirus. The British government is touting the country as a global leader in the big-money investment race to find a vaccine for COVID-19. (Photo by BEN STANSALL / AFP) / TO GO WITH AFP STORY BY JOE JACKSON
Chief Scientific Officer Dr Jeff Drew, uses a microscope to look at cells containing the novel coronavirus SARS-CoV-2 in the Stabilitech laboratory in Burgess Hill south east England, on May 15, 2020 where scientists are trying to develop an oral vaccine for the COVID-19 illness. - The scientists at Stabilitech are one of the teams attempting to develop a vaccine for COVID-19. Ingested in a capsule into the gut, Stabilitech's potential oral vaccine aims to prompt an immune response in mucosal cells in the respiratory system and elsewhere in the body. The firm believes that will be more effective in tackling respiratory illnesses like coronavirus. The British government is touting the country as a global leader in the big-money investment race to find a vaccine for COVID-19. (Photo by BEN STANSALL / AFP) / TO GO WITH AFP STORY BY JOE JACKSON
/ BEN STANSALL
Por Agencia EFE

Científicos de la Universidad de California en Berkeley explicaron a EFE su último hallazgo, por el que un medicamento usado desde los años 50 para controlar el alcoholismo puede ayudar a tratar casos de degeneración retinal que derivan en ceguera.

Conforme a los criterios de

Trust Project
Tipo de trabajo: